Sacituzumab Govitecan Plus Pembrolizumab Prolongs PFS Among Patients with Previously Untreated, PD-L1-positive, Advanced TNBC By Ogkologos - January 30, 2026 200 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ASCENT-04/KEYNOTE-D19 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Indications for Serplulimab Adding Relacorilant to Nab-paclitaxel Prolongs OS in Patients with Platinum-Resistant Ovarian Cancer Quadruplet Isa-KRd Regimen Improves NGS-MRD Negativity in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma MOST POPULAR Today is Veterans Day November 11, 2020 Germline Pathogenic Variants in CDH1, BRCA2, CHEK2, ATM, and PALB2 Associated... October 27, 2021 Why the Fear of Cancer Recurrence Is Often Misunderstood and How... December 6, 2022 ESMO Gastrointestinal Cancers Congress 2024 Munich, Germany, 26-29 June June 14, 2024 Load more HOT NEWS Adding Gemcitabine to Cisplatin Once per Week Concurrently with IMRT Significantly... Outcomes From Second-Line Chemotherapy in Patients with Cholangiocarcinoma and FGFR2 Fusions Genomic Test Helps Identify Thyroid Nodules That Don’t Require Surgery EMA Recommends Granting a Marketing Authorisation for Degarelix Accord
